文献速递骨软组织肉瘤与黑色素瘤

转移性黑色素瘤中PD1为基础治疗获得性耐药的特征与管理

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
PubMed 文献 · Eur J Cancer · 2023-11-20

该多中心研究纳入16个中心299例对PD1为基础治疗有反应后进展的黑色素瘤患者,中位至获得性耐药时间12.6个月(95%CI 11.3-14.2),多数为单器官(65%)和孤立病灶(51%)进展,最常见部位为淋巴结(38%)和脑(25%)。 salvage治疗包括系统治疗(45%)、局部+系统治疗(31%)、局部治疗(21%)或观察(3%),不同管理方式间PFS2或OS无统计学差异;单部位进展较多部位进展2年OS更长(70% vs 54%,p<0.001)。

要点

  • 获得性耐药多表现为寡转移,单器官进展占65%,孤立病灶占51%。
  • 最常见进展部位为淋巴结(38%)和脑(25%)。
  • 单部位进展者2年OS优于多部位进展者(70% vs 54%,p<0.001)。

核心结论

  • 黑色素瘤PD1治疗获得性耐药 largely 为寡转移,患者接受挽救治疗后可能获得较好生存结局。

研究设计与样本

  • 来自16个中心的多中心研究,纳入对PD1为基础治疗有反应后进展的299例黑色素瘤患者,评估 demographics、疾病特征和后续治疗。

主要发现

  • 299例患者中位年龄64岁,44%为BRAFV600m;172例(58%)接受PD1单药,114例(38%)接受PD1/CTLA4,13例(4%)接受PD1联合研究性药物。
  • 90例(30%)为完全缓解(CR),209例(70%)为部分缓解(PR)。
  • 中位至获得性耐药时间为12.6个月(95%CI 11.3-14.2)。
  • 193例(65%)为单器官进展,151例(51%)为孤立病灶进展;最常见部位为淋巴结(38%)和脑(25%)。
  • 获得性耐药时管理包括系统治疗(45%)、局部治疗+系统治疗(31%)、单纯局部治疗(21%)或观察(3%);不同管理方式间PFS2或OS无统计学差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR) within 12 months of treatment experience subsequent disease progression by 6 years. The nature and optimal management of this acquired resistance (AR) remains unknown. METHODS: Pts from 16 centres who responded to PD1-based therapy and who later progressed were examined. Demographics, disease characteristics and subsequent treatments were evaluated. RESULTS: 299 melanoma pts were identified, median age 64y, 44% BRAFV600m. 172 (58%) received PD1 alone, 114 (38%) PD1/CTLA4 and 13 (4%) PD1 and an investigational drug. 90 (30%) pts had CR, 209 (70%) PR. Median time to AR was 12.6 mo (95% CI, 11.3, 14.2). Most (N = 193, 65%) progressed in a single organ site, and in a solitary lesion (N = 151, 51%). The most frequent sites were lymph nodes (38%) and brain (25%). Management at AR included systemic therapy (ST, 45%), local therapy (LT) +ST (31%), LT alone (21%), or observation (3%). There was no statistical difference in PFS2 or OS based on management, however, PFS2 was numerically superior for pts treated with ST alone who progressed off PD1 therapy than those who progressed on PD1 (2-year PFS2 42% versus 25%, p = 0.249). mOS from AR was 38.0 months (95% CI, 29.5-NR); longer in single-site versus multi-site progression (2-year OS 70% vs 54%, p < 0·001). CONCLUSIONS: Acquired resistance to PD1 therapy in melanoma is largely oligometastatic, and pts may have a favorable survival outcome following salvage treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hepner A, Versluis JM, Wallace R, et al. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. Eur J Cancer. 2023. PMID: 37988842. doi:10.1016/j.ejca.2023.113441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。